Advances in chemotherapy in advanced non-small-cell lung cancer

被引：47

作者：

Maione, Paolo ^{[1
]}

Rossi, Antonio ^{[1
]}

Sacco, Paola Claudia ^{[1
]}

Bareschino, Maria Anna ^{[1
]}

Schettino, Clorinda ^{[1
]}

Gridelli, Cesare ^{[1
]}

机构：

[1] SG Moscati Hosp, Div Med Oncol, I-83100 Avellino, Italy

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2010年 / 11卷 / 18期

关键词：

advanced NSCLC; bevacizumab; erlotinib; gefitinib; pemetrexed; platin-based chemotherapy; RANDOMIZED PHASE-III; GEMCITABINE PLUS CARBOPLATIN; 1ST-LINE CHEMOTHERAPY; BEVACIZUMAB; PACLITAXEL; TRIAL; CISPLATIN; THERAPY; ANTIFOLATE; GEFITINIB;

D O I：

10.1517/14656566.2010.511615

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Importance of the field: Lung cancer is the most common cancer in the world today, in terms of both incidence and mortality. Non-small-cell lung cancer (NSCLC) accounts for about 85% of all lung cancers diagnosis, and the majority of people diagnosed with NSCLC have advanced disease. Areas covered in this review: In this review the main advances achieved in the medical treatment of advanced NSCLC are discussed, regarding both targeted therapies and chemotherapy. Among targeted therapies, recent data on the anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab and the epidermal growth factor receptor tyrosyne kinase inhibitors (EGFR-TKIs) gefitinib and erlotinib are described. Among chemotherapeutic agents, the role of pemetrexed is discussed. What the reader will gain: The reader will gain up-to-date information on the main advances, achieved in the last 3 years in the medical treatment of advanced NSCLC. Take home message: Some recent advances have changed the face of the first-line chemotherapy of advanced NSCLC, giving physicians more options to tailor choice in this challenging setting.

引用

页码：2997 / 3007

页数：11

共 50 条

[31] Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial [J].

Pirker, Robert ;

Pereira, Jose R. ;

Szczesna, Aleksandra ;

von Pawel, Joachim ;

Krzakowski, Maciej ;

Ramlau, Rodryg ;

Vynnychenko, Ihor ;

Park, Keunchil ;

Yu, Chih-Teng ;

Ganul, Valentyn ;

Roh, Jae-Kyung ;

Bajetta, Emilio ;

O'Byrne, Kenneth ;

de Marinis, Filippo ;

Eberhardt, Wilfried ;

Goddemeier, Thomas ;

Emig, Michael ;

Gatzemeier, Ulrich ;

Pirker, R. ;

Thatcher, N. ;

Armand, J. P. ;

Camus, P. ;

Victor, N. ;

Emig, M. ;

Mueser, M. ;

Pilz, K. ;

Goddemeier, T. ;

Montaner, I. ;

Lachs, Martin ;

Hoang-Sayag, Loan ;

Alvarez, A. ;

Coppola, F. ;

Recondo, G. ;

Richardet, E. ;

Kirsten, F. ;

Karapetis, C. ;

Parente, P. ;

Michael, M. ;

White, S. ;

Boyce, A. ;

Lewis, C. ;

Slancar, M. ;

Pavlakis, N. ;

Abdi, E. ;

Underhill, C. ;

Pittman, K. ;

Burghuber, O. ;

Pirker, R. ;

Ruckser, R. ;

Ulsperger, E. .

LANCET, 2009, 373 (9674) :1525-1531

[32] Dacomitinib for the treatment of advanced or metastatic non-small-cell lung cancer [J].

Mok, Tony ;

Lee, Kirsty ;

Tang, Michael ;

Leung, Linda .

FUTURE ONCOLOGY, 2014, 10 (05) :813-822

[33] Maintenance therapy for advanced non-small-cell lung cancer: switch versus continuation [J].

Joshi, Monika ;

Jiang, Yixing ;

Belani, Chandra P. .

EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (05) :685-697

[34] Clinical Trials of Vascular Disrupting Agents in Advanced Non-Small-Cell Lung Cancer [J].

McKeage, Mark J. .

CLINICAL LUNG CANCER, 2011, 12 (03) :143-147

[35] Systemic Therapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancers [J].

Bunn, Paul A., Jr. ;

Dimou, Anastasios .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (25) :2571-+

[36] Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer [J].

Soria, J. -C. ;

Ohe, Y. ;

Vansteenkiste, J. ;

Reungwetwattana, T. ;

Chewaskulyong, B. ;

Lee, K. H. ;

Dechaphunkul, A. ;

Imamura, F. ;

Nogami, N. ;

Kurata, T. ;

Okamoto, I. ;

Zhou, C. ;

Cho, B. C. ;

Cheng, Y. ;

Cho, E. K. ;

Voon, P. J. ;

Planchard, D. ;

Su, W. -C. ;

Gray, J. E. ;

Lee, S. -M. ;

Hodge, R. ;

Marotti, M. ;

Rukazenkov, Y. ;

Ramalingam, S. S. ;

Boyer, Michael ;

Lee, Chee ;

Hughes, Brett ;

O'Byrne, Kenneth ;

Briggs, Peter ;

Milward, Michael ;

John, Thomas ;

Demedts, Ingel ;

Vansteenkiste, Johan ;

Bustin, Frederique ;

Barrios, Carlos Henrique ;

Timcheva, Constanta ;

Butts, Charles ;

Goss, Glenwood ;

Juergens, Rosalyn ;

Leighl, Natasha ;

Cheng, Susanna ;

Burkes, Ronald ;

Zhou, Caicun ;

Zhang, Helong ;

Shu, Yongqian ;

Cheng, Ying ;

Zhou, Qing ;

Li, Wei ;

Feng, Guosheng ;

He, Yong .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02) :113-125

[37] Second-Line Therapy for Non-Small-Cell Lung Cancer [J].

Arango, Belisario A. ;

Castrellon, Aurelio B. ;

Santos, Edgardo S. ;

Raez, Luis E. .

CLINICAL LUNG CANCER, 2009, 10 (02) :91-98

[38] EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis [J].

Chen, Peng ;

Wang, Long ;

Liu, Bing ;

Zhang, Hai-Zhong ;

Liu, Hong-Chen ;

Zou, Zui .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 67 (03) :235-243

[39] A prognostic model for platinum-doublet as second-line chemotherapy in advanced non-small-cell lung cancer patients [J].

Mo, Hongnan ;

Hao, Xuezhi ;

Liu, Yutao ;

Wang, Lin ;

Hu, Xingsheng ;

Xu, Jianping ;

Yang, Sheng ;

Xing, Puyuan ;

Shi, Youwu ;

Jia, Bo ;

Wang, Yan ;

Li, Junling ;

Wang, Hongyu ;

Wang, Ziping ;

Sun, Yan ;

Shi, Yuankai .

CANCER MEDICINE, 2016, 5 (06) :1116-1124

[40] The efficacy and safety of bevacizumab in addition to platinum-based chemotherapy for the first-line treatment of patients with advanced nonsquamous non-small-cell lung cancer: Final results of AVALANCHE, an observational cohort study [J].

Tolnay, Edina ;

Ghimessy, Aron Kristof ;

Juhasz, Erzsebet ;

Sztancsik, Zsuzsanna ;

Losonczy, Gyorgy ;

Dombi, Peter ;

Vennes, Zsuzsanna ;

Helf, Laszlo ;

Csada, Edit ;

Sarosi, Veronika .

ONCOLOGY LETTERS, 2019, 17 (02) :1750-1760

← 1 2 3 4 5 →